The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

Not specified

Study Completion Date

January 31, 2000

Conditions
HIV Infections
Interventions
DRUG

Hydroxyurea

DRUG

Didanosine

Trial Locations (18)

10003

Beth Israel Med Ctr, New York

10016

Bellevue Hosp / New York Univ Med Ctr, New York

10029

Mount Sinai Med Ctr, New York

19104

Univ of Pennsylvania at Philadelphia, Philadelphia

21287

Johns Hopkins Hosp, Baltimore

27710

Duke Univ Med Ctr, Durham

29169

Julio Arroyo, West Columbia

44106

Case Western Reserve Univ, Cleveland

80262

Univ of Colorado Health Sciences Ctr, Denver

90502

Harbor UCLA Med Ctr, Torrance

94115

Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco

191075098

Thomas Jefferson Univ Hosp, Philadelphia

275997215

Univ of North Carolina, Chapel Hill

441091998

MetroHealth Med Ctr, Cleveland

452670405

Univ of Cincinnati, Cincinnati

921036325

Univ of California / San Diego Treatment Ctr, San Diego

943055107

Stanford Univ Med Ctr, Stanford

981224304

Univ of Washington, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH